Oppositional Defiant Disorder Completed Phase 4 Trials for Atomoxetine (DB00289)

Also known as: Conduct Disorder / Disruptive Behavior Disorders / Disruptive behaviour disorder / Disruptive Behavior Disorder / Conduct Disorders / Behavior Disorder, Disruptive / Conduct behavior disorder / Conduct behaviour disorder / Unspecified disturbance of conduct

IndicationStatusPhase
DBCOND0032311 (Oppositional Defiant Disorder)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00406354Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in GermanyTreatment